May 1, 2004
Boston Cure Project
Here's a quick negative study that found that Interferon beta-1a (Rebif(R)), 22 micro g subcutaneously once weekly, in patients with secondary progressive MS did not delay progression of disease. My guess is they'll try higher doses next.
Copyright © 2004, Boston Cure Project